.jpg)
16 hours ago
1
Article content
CAMBRIDGE, Mass. — Cognito Therapeutics, a clinical-stage medical device company pioneering non-invasive neuroprotection therapies against neurodegenerative diseases, today announced that five abstracts featuring its lead investigational device, Spectris™, have been accepted for presentation at the Alzheimer’s Association International Conference (AAIC) 2025, taking place July 27–31 in Toronto, Canada.
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account
- Share your thoughts and join the conversation in the comments
- Enjoy additional articles per month
- Get email updates from your favourite authors
Sign In or Create an Account
or
Article content
The presentations will showcase clinical, neurophysiological, and biomarker data supporting Spectris™, an at-home device designed to deliver personalized, sensory-driven gamma stimulation to slow the progression of Alzheimer’s disease.
Article content
Article content
Article content
Among the highlights is an oral presentation selected by the International Society to Advance Alzheimer’s Research and Treatment (ISTAART):
Article content
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
- Preservation of Neurophysiological Signals and White Matter with 40Hz Sensory Stimulation in Alzheimer’s Disease
Session: ISTAART Oral Session
Presenter: Chandran Seshagiri, PhD
Date/Time: Saturday, July 26, 2025, 10:15–11:15 AM
Article content
In addition, Cognito will present five poster sessions:
Article content
- Sensory-evoked gamma oscillation reduces white matter loss and preserves myelin in Alzheimer’s disease: neuroimaging and proteomics findings
Presenter: Mihaly Hajos, PhD
Date/Time: Sunday, July 27, 7:30 AM – 4:15 PM - Spectris non-invasive neuromodulation in Alzheimer’s disease
Presenter: Ralph Kern, MD, MHSc
Date/Time: Monday, July 28, 7:30 AM – 4:15 PM - Exploration of an instrument measuring outcomes most important to patients through analysis of OVERTURE data
Presenter: Lily Lee, PhD
Date/Time: Tuesday, July 29, 7:30 AM – 4:15 PM - Spectris™ combined audiovisual sensory stimulation elicits stronger EEG brain response than auditory or visual stimulation alone
Presenter: Chandran Seshagiri, PhD
Date/Time: Wednesday, July 30, 7:30 AM – 4:15 PM - Spectris™ treatment is associated with significant time saved in the OVERTURE feasibility and open-label extension (OLE) study
Presenter: Lily Lee, PhD
Date/Time: Wednesday, July 30, 7:30 AM – 4:15 PM
Article content
“These presentations underscore the broad neuroprotective potential of Spectris, from preserving white matter and functional connectivity to measuring real-world benefits that matter to patients,” said Ralph Kern, MD, MHSc, Chief Medical Officer of Cognito Therapeutics. “We look forward to sharing these latest insights with the global neuroscience community at AAIC.”
Article content
Spectris™ is currently being evaluated in the ongoing HOPE pivotal clinical trial (NCT05637801) for Alzheimer’s disease. It is an investigational device and has not yet received regulatory approval for commercial use from the U.S. Food and Drug Administration or any other health authority.
Article content
About Cognito Therapeutics
Article content
Cognito Therapeutics is a late clinical-stage medical device company pioneering neuroprotective therapies to address the unmet needs of patients living with CNS disorders. Its lead product, Spectris™ AD, is an at-home therapeutic device that uses non-invasive, sensory-driven neurostimulation to evoke gamma frequency brain activity. The company’s feasibility studies have shown the potential for Spectris AD to preserve cognition, daily function, and slow brain atrophy in patients diagnosed with mild-to-moderate AD. Cognito is headquartered in Cambridge, MA. For more information, visit www.cognitotx.com and follow @cognitotx.
Article content
Article content
Article content
Article content
View source version on businesswire.com:
Article content
Article content
Article content
Contacts
Article content
Media Contact
Article content
Article content
Kimberly Ha
Article content
Article content
KKH Advisors
Article content
Article content
917-291-5744
Article content
Article content
Article content
Article content
English (US)